Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience

Haematologica. 2007 Feb;92(2):271-2. doi: 10.3324/haematol.10737.

Abstract

Novel, effective therapies are needed for peripheral T-cell non-Hodgkin's lymphoma (PTCL). We treated 16 patients with a combination of gemcitabine, cisplatin and methylprednisolone (GEM-P). Three patients (19%) achieved a complete remission and eight (50%) a partial remission. GEM-P has encouraging efficacy with an acceptable toxicity profile in patients with PTCL.

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / administration & dosage*
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Female
  • Gemcitabine
  • Humans
  • Lymphoma, T-Cell, Peripheral / drug therapy*
  • Male
  • Methylprednisolone / administration & dosage*
  • Middle Aged
  • Prognosis
  • Remission Induction
  • Treatment Outcome

Substances

  • Deoxycytidine
  • Cisplatin
  • Methylprednisolone
  • Gemcitabine